Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Buy
59
ELAN Quote, Financials, Valuation and Earnings
Last price:
$26.08
Seasonality move
:
-3.78%
Day range:
$25.70 - $26.35
52-week range:
$8.02 - $27.72
Dividend yield:
0%
P/E ratio:
339.51x
P/S ratio:
2.76x
P/B ratio:
1.98x
Volume:
3.2M
Avg. volume:
4.8M
1-year change:
133.57%
Market cap:
$13B
Revenue:
$4.7B
EPS (TTM):
-$0.47
Analysts' Opinion
-
Consensus RatingElanco Animal Health, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 10 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $28.77, Elanco Animal Health, Inc. has an estimated upside of 10.27% from its current price of $26.09.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $20.00 representing 100% downside risk from its current price of $26.09.
Fair Value
-
According to the consensus of 12 analysts, Elanco Animal Health, Inc. has 10.27% upside to fair value with a price target of $28.77 per share.
ELAN vs. S&P 500
-
Over the past 5 trading days, Elanco Animal Health, Inc. has overperformed the S&P 500 by 6.4% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Elanco Animal Health, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Elanco Animal Health, Inc. has grown year-over-year revenues for 3 quarters straight. In the most recent quarter Elanco Animal Health, Inc. reported revenues of $1.1B.
Earnings Growth
-
Elanco Animal Health, Inc. earnings have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Elanco Animal Health, Inc. reported earnings per share of -$0.56.
Enterprise value:
16.6B
EV / Invested capital:
1.55x
Price / LTM sales:
2.76x
EV / EBIT:
65.71x
EV / Revenue:
3.51x
PEG ratio (5yr expected):
-0.01x
EV / Free cash flow:
58.31x
Price / Operating cash flow:
45.77x
Enterprise value / EBITDA:
17.77x
Gross Profit (TTM):
$2.1B
Return On Assets:
-1.75%
Net Income Margin (TTM):
-4.92%
Return On Equity:
-3.57%
Return On Invested Capital:
-2.16%
Operating Margin:
1.66%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Income Statement | ||||||
| Revenue | $4.4B | $4.4B | $4.7B | $1B | $1.1B | |
| Gross Profit | $1.9B | $1.9B | $2.1B | $389M | $450M | |
| Operating Income | $326M | $251M | $252M | $8M | $19M | |
| EBITDA | $1B | $913M | $932M | $172M | $193M | |
| Diluted EPS | -$2.50 | $0.68 | -$0.47 | -$0.02 | -$0.56 | |
| Period Ending | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $3.3B | $3.3B | $3.4B | $3.2B | $3.5B | |
| Total Assets | $16.5B | $15.5B | $14.4B | $12.6B | $13.4B | |
| Current Liabilities | $1.6B | $1.7B | $1.2B | $1.3B | $1.6B | |
| Total Liabilities | $9B | $8.2B | $8.1B | $6.5B | $6.8B | |
| Total Equity | $7.5B | $7.3B | $6.2B | $6.1B | $6.5B | |
| Total Debt | $6.4B | $5.9B | $5.9B | $4.4B | $4.1B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $271M | $541M | $560M | $177M | $108M | |
| Cash From Investing | -$169M | $1.2B | -$279M | -$90M | -$64M | |
| Cash From Financing | -$83M | -$1.5B | -$275M | -$32M | -$18M | |
| Free Cash Flow | $117M | $380M | $284M | $124M | $46M | |
ELAN
Sector
Market Cap
$13B
$25.6M
Price % of 52-Week High
94.12%
50%
Dividend Yield
0%
0%
Shareholder Yield
0.38%
-1.62%
1-Year Price Total Return
133.57%
-18.97%
Beta (5-Year)
1.833
0.490
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$25.85
200-day SMA
Buy
Level
$19.41
Bollinger Bands (100)
Buy
Level
21.33 - 24.59
Chaikin Money Flow
Sell
Level
-128.5M
20-day SMA
Buy
Level
$25.28
Relative Strength Index (RSI14)
Buy
Level
58.87
ADX Line
Buy
Level
18.77
Williams %R
Neutral
Level
-38.9021
50-day SMA
Buy
Level
$24.19
MACD (12, 26)
Buy
Level
0.58
25-day Aroon Oscillator
Buy
Level
4
On Balance Volume
Sell
Level
-48.3M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (1.3442)
Buy
CA Score
(Annual)
Level (-0.2962)
Buy
Beneish M-Score
(Annual)
Level (-2.6655)
Buy
Momentum Score
Level (9)
Buy
Ohlson Score
Level (-1.8667)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (6)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Elanco Animal Health, Inc. develops, manufactures, and markets products for pets and farm animals. Its products include Advantage Family, Atopica, Credelio Family, Drontal Family, Galliprant, Interceptor Plus, Milbemax, Onsior, Seresto, Trifexis, TruCan, AviPro, Baytril, Catosal, Denagard, and Experior. The company was founded in 1954 and is headquartered in Indianapolis, IN.
Stock Forecast FAQ
In the current month, ELAN has received 10 Buy ratings 2 Hold ratings, and 0 Sell ratings. The ELAN average analyst price target in the past 3 months is $28.77.
-
Where Will Elanco Animal Health, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Elanco Animal Health, Inc. share price will rise to $28.77 per share over the next 12 months.
-
What Do Analysts Say About Elanco Animal Health, Inc.?
Analysts are divided on their view about Elanco Animal Health, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Elanco Animal Health, Inc. is a Sell and believe this share price will drop from its current level to $20.00.
-
What Is Elanco Animal Health, Inc.'s Price Target?
The price target for Elanco Animal Health, Inc. over the next 1-year time period is forecast to be $28.77 according to 12 Wall Street analysts, 10 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is ELAN A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Elanco Animal Health, Inc. is a Buy. 10 of 12 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ELAN?
You can purchase shares of Elanco Animal Health, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Elanco Animal Health, Inc. shares.
-
What Is The Elanco Animal Health, Inc. Share Price Today?
Elanco Animal Health, Inc. was last trading at $26.08 per share. This represents the most recent stock quote for Elanco Animal Health, Inc.. Yesterday, Elanco Animal Health, Inc. closed at $26.09 per share.
-
How To Buy Elanco Animal Health, Inc. Stock Online?
In order to purchase Elanco Animal Health, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get ELAN Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
ELAN
Sector
P/E ratio
339.51x
23.22x
PEG ratio
-0.01x
-0.01x
P/B ratio
1.98x
1.80x
Price / LTM sales
2.76x
1.53x
Growth Metrics
ELAN
Sector
Revenue growth
12.16%
3.44%
Earnings growth
-3328.4%
11.15%
Revenue (5-year growth)
7.57%
6.46%
Earnings forecast
$0.11
-$0.19
Profitability
ELAN
Sector
Profitability FY 2025
$2.1B
$2.4M
Return on invested capital
-2.16%
-33.43%
Return on assets
-1.75%
-29.79%
Return on equity
-3.57%
-39.31%
Earnings Date
Last Earnings Date
Feb
24
Next Earnings Date
May
7
Estimated Next Earnings Date
May
26
Balance Sheet
ELAN
Sector
Total cash
$545M
$24.1M
Short term investments
--
$23.8M
Total assets
$13.4B
$70.2M
Long term debt
$4.1B
$2.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
49
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 37x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
37
Is GOOGL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Sell
50
AXTI alert for Mar 3
AXT, Inc. [AXTI] is down 13.86% over the past day.
Buy
53
AAOI alert for Mar 3
Applied Optoelectronics, Inc. [AAOI] is down 7.76% over the past day.
Sell
32
TPB alert for Mar 3
Turning Point Brands, Inc. [TPB] is down 3.24% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
